Clinical reserch of stroke-associated pneumonia prevented with ramipril
10.3760/cma.j.issn.0254-9026.2014.09.007
- VernacularTitle:雷米普利预防卒中相关性肺炎的临床研究
- Author:
Yu LIU
;
Hong LI
;
Xiuli ZHAO
;
Yongjun ZHENG
;
Ruihua SONG
;
Xiaoguang SU
- Publication Type:Journal Article
- Keywords:
Ramipril;
Stroke;
Pneumonia
- From:
Chinese Journal of Geriatrics
2014;33(9):952-954
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the prevention of stroke-associated pneumonia (SAP) with Ramipril.Methods 404 acute stroke patients with primary hypertension were randomized into two groups.Group A received ramipril 2.5 mg once daily orally,and then were titrated up to 5 mg/d after a week.Group B received Candesartan 4 mg once daily orally,and then were titrated up to 8 mg/d after a week.The treatment course was 28 days.All patients received examination of Standardized Swallowing Assessment (SSA).The amelioration of swallow function and incidence of SAP after treatment were compared between the two groups.Results There were 10 patients suffering from SAP in group A and 21 patients in group B.The incidence of SAP was lower in group A(5.0％)than in group B(10.4％)(P＜0.05).The positive rate of SSA was 87.1 ％ in patients with SAP,higher than the total rate (47.5％).Dysphagia was improved in both groups after treatment.The rate of dysphagia improvement in group A and group B was 81.4％ and 66.3％ respectively.There was significant statistics difference in the positive case of SSA between two group (P＜ 0.05).Conclusions Orally treatment with ramipril is effective to prevent stroke-associated pneumonia and toimprove swallow function.
